Sanofi
Sanofi is a biopharmaceutical company that researches, develops and manufactures medicines and vaccines for patients around the world. Its single operating segment, Biopharma, includes commercial operations and research, development and production across Specialty Care, General Medicines and Vaccines, as well as support and corporate functions. Its activities are organized around Immunology, Rare Diseases, Neurology, Oncology, Other Medicines and Vaccines. Products include Dupixent, and its portfolio includes medicines and vaccines for conditions such as immune-mediated diseases, rare diseases and infections. Sanofi makes money from commercializing its medicines and vaccines, and from manufacturing Consumer Healthcare products invoiced to Opella Healthcare SAS. It also includes in its Biopharma segment the purchase price of Biopharma products manufactured by Opella. Sanofi is headquartered in Paris, France.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $SNY in the last 30 days.
See all $SNY insider activity →DRAP issued alerts about counterfeit flu vaccines in Pakistan, falsely labeled as Influvac Tetra (Abbott) and Vaxigrip Tetra (Sanofi). Both companies confirmed the vaccines are fake. DRAP warned of serious health risks and urged reporting of suspicious batches. Provincial authorities were directed to seize affected stock.
The Nasdaq dropped 2.9% to a three-month low, with Intel and Amazon.com leading declines. Intel fell 29% after a weak outlook, while Amazon dropped 1% on missed earnings. Reddit also fell 29% despite revenue growth. ExxonMobil and Chevron rose on strong earnings, and Regeneron gained on revenue growth and a collaboration deal. Employment costs rose 0.8% in September, and the Chicago PMI decreased to 55.30.
Sanofi reported Q3 sales of €14.44bn, up 14.3% YoY, driven by strong performance of Dupixent. The company faces leadership changes, pipeline setbacks, and future patent expirations for Dupixent.
Over the past 7 days, AlphAI's AI scored 37 news stories mentioning SNY (Sanofi). Coverage has skewed bullish: 31 bullish, 3 neutral, and 3 bearish.
Recent SNY coverage spans earnings, financial news and regulation.
Negative pressure as market reacts to counterfeit alert and possible sales impact in Pakistan.
Collaboration adds upside potential for Sanofi.
Strong sales growth may support the stock price, though future Dupixent patent expiries could temper upside.
Sanofi’s entry into a novel Alzheimer’s therapy pathway could boost its biotech pipeline valuation.
Sanofi posted strong earnings and raised its 2026 sales and EPS outlook.
AlphAI scores every news story that mentions SNY with an AI model for sentiment and relevance, and aggregates insider trades from Sanofi's SEC EDGAR Form 4 filings. Figures refresh continuously.
DRAP issued alerts about counterfeit flu vaccines in Pakistan, falsely labeled as Influvac Tetra (Abbott) and Vaxigrip Tetra (Sanofi). Both companies confirmed the vaccines are fake. DRAP warned of serious health risks and urged reporting of suspicious batches. Provincial authorities were directed to seize affected stock.
The Nasdaq dropped 2.9% to a three-month low, with Intel and Amazon.com leading declines. Intel fell 29% after a weak outlook, while Amazon dropped 1% on missed earnings. Reddit also fell 29% despite revenue growth. ExxonMobil and Chevron rose on strong earnings, and Regeneron gained on revenue growth and a collaboration deal. Employment costs rose 0.8% in September, and the Chicago PMI decreased to 55.30.
Sanofi reported Q3 sales of €14.44bn, up 14.3% YoY, driven by strong performance of Dupixent. The company faces leadership changes, pipeline setbacks, and future patent expirations for Dupixent.
Sanofi's SAR448851, an oral Alzheimer's drug activating TREM2, showed target engagement in a Phase 1 trial and is advancing to Phase 2. The drug, acquired from Vigil Neuroscience, is the first small-molecule TREM2 agonist to reach this stage, offering a potential new approach to clearing amyloid plaques by boosting the brain's immune response.
Sanofi (SNY) furnished an SEC Form 6-K — earnings release. Press Release Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded October 30, 2026 Q3 sales growth of 14.3% at CER 1 and business earnings per share (EPS) 2 of €3.55 • Pharma launches sales increased by 31.4%, reaching €1.4 billion, driven by ALTUVII
Sanofi's CFO indicates the company is open to larger acquisitions, potentially exceeding its typical $2-5 billion range, to support its pipeline and address the upcoming Dupixent patent cliff. With Q3 earnings beating expectations, analysts estimate Sanofi has €20 billion in deal capacity. The company plans to focus on immunology, rare diseases, and vaccines, with possible forays into other high-need areas.
Sanofi raised its 2026 sales growth forecast to a low-teens percentage, up from 10%, citing strong demand for Dupixent. The company also expects business operating income per share to grow by a mid-teens percentage. CEO Belen Garijo is leading a strategic review, with analysts suggesting M&A is needed for new experimental drugs. CFO François Roger indicated interest in larger deals, focusing on rare diseases, vaccines, and immunology.
Sanofi has tentatively agreed to settle a decade-old antitrust lawsuit alleging it delayed generic competition for its diabetes drug Lantus. The company and distributors filed a joint motion in Massachusetts federal court to pause proceedings. The settlement amount remains undisclosed.
Sanofi Canada will expand the availability of its protein-based COVID-19 vaccine, Nuvaxovid, to 10 provinces and Yukon for the 2026-2027 respiratory season. The vaccine, which has shown 90% efficacy in preventing symptomatic COVID-19, will be available through provincial programs and private insurers. Sanofi aims to provide Canadians with more vaccine options, particularly for those with compromised immune systems.
Pakistan faces a shortage of flu vaccines from major suppliers like Abbott, Sanofi, Sinovac, and Shenzhen Innovax. Drug inspectors seized suspected counterfeit vaccines in Lahore. Abbott may not supply any this year, while Sanofi's delivery is delayed. Authorities warn the public to buy from licensed pharmacies and verify product authenticity.
